Cryo-Cell International (CCEL) vs Viemed Healthcare (VMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Viemed Healthcare (VMD) has outperformed Cryo-Cell International (CCEL) over the past year, gaining 27.9% versus a gain of 1.5%. Over five years, VMD leads with a +62.9% price change compared with -66.3% for CCEL. Viemed Healthcare is the larger company by market cap ($322.8 million vs $33.5 million), about 9.6 times the size.
On valuation, Viemed Healthcare trades at a lower forward P/E (21.3x vs 207.5x for Cryo-Cell International). Viemed Healthcare converts more of its revenue into profit, with a net margin of 5.5% versus -7.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCEL | VMD |
|---|---|---|
| Share price | $4.15 | $8.52 |
| Market cap | $33.46M | $322.85M |
| 1-day change | 0.00% | -1.05% |
| YTD return | +20.64% | +14.67% |
| 1-year return | +1.47% | +27.93% |
| 5-year return | -66.34% | +62.91% |
| P/E ratio (TTM) | — | 22.42 |
| Forward P/E | 207.50 | 21.30 |
| EPS (TTM) | $-0.24 | $0.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $31.57M | $270.28M |
| Revenue growth (YoY) | -1.31% | +20.52% |
| Net income (latest FY) | $-2.43M | $14.93M |
| Gross margin | 76.63% | 57.52% |
| Operating margin | 1.53% | 8.49% |
| Net margin | -7.70% | 5.53% |
| 52-week high | $5.45 | $12.61 |
| 52-week low | $2.72 | $6.60 |
| Distance from 52-week high | -23.85% | -32.43% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +40.85% |
| Average volume | 13.02K | 247.43K |
| Shares outstanding | 8.06M | 37.89M |
| Employees | 72 | 1,490 |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Viemed Healthcare is about 9.6 times larger than Cryo-Cell International by market value ($322.85M vs $33.46M).
- VMD has outperformed CCEL by 26.5 percentage points over the past year.
- Viemed Healthcare is more profitable, keeping 5.5 cents of every revenue dollar as net income versus -7.7 cents for Cryo-Cell International.
- Viemed Healthcare grew revenue faster in its latest fiscal year (+20.52% vs -1.31%).
About Cryo-Cell International
CCEL stock →Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States.
Health Care · Misc Health and Biotechnology Services · 72 employees
About Viemed Healthcare
VMD stock →Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.
Health Care · Misc Health and Biotechnology Services · 1,490 employees
CCEL vs VMD FAQ
Which is bigger, Cryo-Cell International or Viemed Healthcare?
Viemed Healthcare (VMD) is larger, with a market capitalization of $322.85M compared with $33.46M for Cryo-Cell International (CCEL).
Which stock has performed better over the past year, CCEL or VMD?
VMD returned +27.93% over the past 12 months, compared with +1.47% for CCEL (price return, excluding dividends). Past performance does not predict future results.
Are Cryo-Cell International and Viemed Healthcare in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.